Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation

a technology of etiolate and metabolites, applied in the field of pharmaceutical chemistry, can solve the problems of limited use, significant side effects, and lack of durable efficacy of traditional treatments

Inactive Publication Date: 2011-04-07
CHELSEA THERAPEUTICS
View PDF23 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional treatments, however, suffer limitations including significant side effects, lack of durable efficacy, and inconvenient administration schedules.
Current therapies, however, are ineffective in many patients and present significant side effects including slow onset of action and toxicity.
Intrinsic and acquired resistance to MTX and other antifolate analogues limits their clinical effectiveness, however.
Apart from resistance, major limitations of MTX treatment include bone marrow toxicity, gastrointestinal ulceration and liver and kidney damage.
Early clinical trials, however, were confounded by cumulative myelosuppression that prevented repetitive administration (Roberts J D.
In 1991, Nair et al. demonstrated that contrary to the widely accepted notion, polyglutamylation of classical antifolates is not essential for anti-tumor activity and further, that this metabolic transformation is actually undesirable because it may cause the loss of pharmacological control and target specificity of the drug (Nair M G et al.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation
  • Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation
  • Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Inhibition of Dihydrofolate Reductase and Thymidylate Synthase

The ability of M-TREX to inhibit recombinant dihydrofolate reductase (DR) and thymidylate synthase (TS) in vitro studied in comparison to other antifolate drugs. The results are summarized in Table 1:

CompoundI50 (human DHFR)I50 (Human TS)MTX1.7 × 10−8M—TOMUDEX—1.0 × 10−6MMDAM4.4 × 10−8M—MTA (LY-231514)6.6 × 10−6M1.1 × 10−5MM-TREX1.7 × 10−8M3.8 × 10−6M

These results establish that M-TREX is a potent inhibitor of both DHFR and TS.

example 2

Formulation of MTREX in a Microcrystalline Cellulose Capsule

Materials

Avicel PH 101 will be used to dilute the drug to the required dose strengths prior to capsule filling. Additional materials are listed in Table 1.

TABLE 1MaterialGradeFunctionSupplierAvicel PH101EPFiller / HONEYWILL &(Microcrystalline Cellulose)DiluentSTEINWhite Hard Gelatin CapsulesEPShellCAPSUGELSize 0

A Semi-automated capsule filler, such as a Feton Plate and a blender, such as a Turbula—Drum will be used to formulate the drug.

Methods

LOD—Loss On Drying

The LOD will be measured using Sartorius MA45 infra-red balance. The program selected for the analysis will be dependant on the physical properties of the drug. An appropriate sample size will be weighed out onto the aluminum tray of the LOD balance. Care will be taken to ensure that sample is leveled and in the middle of the tray, with no gaps. Using the appropriate method, the loss on drying analysis will be performed. The LOD value will be recorded in percentage.

Car...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and / or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.

Description

FIELD OF THE INVENTIONThe invention is in the area of pharmaceutical chemistry, and is in particular, metabolically inert etiolate compounds for the prevention and treatment of disorders of abnormal cell proliferation and / or inflammation, such as psoriasis and Crohn's disease.BACKGROUND OF THE INVENTIONDisorders of abnormal cell proliferation are characterized by inappropriate growth or multiplication of one or more cell types. They include malignant (i.e., cancer) as well as non-malignant disorders. Many of these diseases also include an inflammatory component. Psoriasis represents one type of non-malignant disorder of abnormal cell proliferation. The disorder is characterized by psoriatic skin plaques representing highly localized sites of deregulated growth and inflammation. While the cause of psoriasis is poorly understood, it is thought to involve both a genetic and environmental component. Moderate-to-severe psoriasis has traditionally been treated with systemic therapies such...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K31/517A61K31/573A61K38/16A61P35/00A61P19/02A61P29/00A61P3/00A61P25/28A61P11/06A61P25/16
CPCC07D239/95A61P1/00A61P11/00A61P11/06A61P11/16A61P13/00A61P13/12A61P15/00A61P15/02A61P17/00A61P17/02A61P17/06A61P17/18A61P19/02A61P25/00A61P25/16A61P25/18A61P25/28A61P27/02A61P29/00A61P3/00A61P31/04A61P35/00A61P37/00A61P37/02A61P37/08A61P43/00A61P7/00A61P9/00A61P9/08A61P9/10A61P9/12A61P3/10
Inventor ROBERTS, MICHAEL J.PEDDER, SIMON
Owner CHELSEA THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap